Seaport Therapeutics
SPTX
17.93
+0.56
+3.22%
Seaport Therapeutics
US · SPTX
#3277 by market cap
Listed 2026
17.93
+0.56
+3.22%
Live - 5344 symbols - heartbeat 277s ago
· 2026-10-07 20:02
After-hours
17.93
0.00%
- Market cap
- 959.80M
- P/E (TTM)i
- -7.13
- P/Bi
- 2.27
- EPSi
- -1.41
- Div yieldi
- 0.00%
- 52W posi
- 23%
Reader sentiment
Are you bullish or bearish on SPTX?
Anonymous reader poll. Unscientific, not investment advice.
Revenue annual, last 2 years
Income statement
| Line item | 2024 | 2025 |
|---|---|---|
| Revenue | -- | -- |
| Gross profit | -- | -- |
| Selling & admin expenses | 27.35M | 20.98M |
| Research & development | 25.07M | 66.31M |
| Operating profit | -52.42M | -87.29M |
| Pretax profit | -46.88M | -74.11M |
| Tax | 0 | 773.00K |
| Net profit | -46.88M | -74.88M |
| Basic EPS | -1 | -2 |
| Diluted EPS | -1.21 | -1.94 |
| Line item | 2025-03 | 2025-06 | 2026-03 | 2026-06 |
|---|---|---|---|---|
| Revenue | -- | -- | -- | -- |
| Gross profit | -- | -- | -- | -- |
| Selling & admin expenses | 5.65M | 5.06M | 6.11M | 41.19M |
| Research & development | 10.53M | 13.41M | 21.43M | 24.62M |
| Operating profit | -16.19M | -18.47M | -27.54M | -65.81M |
| Pretax profit | -13.09M | -14.94M | -24.89M | -62.35M |
| Tax | 31.00K | 134.00K | 519.00K | 251.00K |
| Net profit | -13.13M | -15.08M | -25.41M | -62.60M |
| Basic EPS | 0 | 0 | 0 | -2 |
| Diluted EPS | -0.34 | -0.39 | -0.48 | -1.78 |
Balance sheet
| Line item | 2024 | 2025 |
|---|---|---|
| Total current assets | 310.15M | 223.23M |
| Cash & ST investments | 309.10M | 215.98M |
| Inventory | -- | -- |
| Total assets | 315.78M | 249.01M |
| Total current liabilities | 11.15M | 12.78M |
| Short-term debt | 857.00K | 1.64M |
| Long-term debt | -- | -- |
| Total liabilities | 340,626,000.00 | 341,554,000.00 |
| Total equity | -24.85M | -92.55M |
| Retained earnings | -39.23M | -114.11M |
| Line item | 2025-03 | 2025-06 | 2026-03 | 2026-06 |
|---|---|---|---|---|
| Total current assets | -- | -- | 188.34M | 282.18M |
| Cash & ST investments | -- | -- | 182.61M | 273.31M |
| Inventory | -- | -- | -- | -- |
| Total assets | -- | -- | 227.67M | 441.68M |
| Total current liabilities | -- | -- | 14.22M | 15.67M |
| Short-term debt | -- | -- | 1.60M | 1.61M |
| Long-term debt | -- | -- | -- | -- |
| Total liabilities | -- | -- | 343,294,000.00 | 19,079,000.00 |
| Total equity | -- | -- | -115.62M | 422.60M |
| Retained earnings | -- | -- | -139.52M | -202.12M |
Cash flow
| Line item | 2024 | 2025 |
|---|---|---|
| Operating cash flow | -29.63M | -77.94M |
| Depreciation & amortization | 214.00K | 1.41M |
| Free cash flow | -29.74M | -78.30M |
| Dividends paid | -- | -- |
| Stock buybacks / issuance | -- | -- |
| Ending cash balance | 309.55M | 46.50M |
| Line item | 2025-03 | 2025-06 | 2026-03 | 2026-06 |
|---|---|---|---|---|
| Operating cash flow | -20.21M | -15.33M | -20.17M | -26.14M |
| Depreciation & amortization | 315.00K | 354.00K | 357.00K | 351.00K |
| Free cash flow | -20.26M | -15.59M | -20.17M | -26.14M |
| Dividends paid | -- | -- | -- | -- |
| Stock buybacks / issuance | -- | -- | -- | -- |
| Ending cash balance | 63.80M | 47.03M | 53.36M | 64.68M |
Returns & efficiency
| Line item | 2024 | 2025 |
|---|---|---|
| ROE %i | -- | -- |
| ROA %i | -14.85 | -26.52 |
| ROIC %i | -- | -- |
| 5-year avg ROE %i | -- | -- |
| EBIT margin %i | -- | -- |
| FCF / sales %i | -- | -- |
| Current ratioi | 27.82 | 17.46 |
| Quick ratioi | 27.72 | 17.13 |
| Debt / assetsi | 1.59 | 2.04 |
| LT debt / equityi | -- | -- |
| Interest coveragei | -- | -- |
| Revenue CAGR (3Y) %i | -- | -- |
| Net income CAGR (3Y) %i | -- | -- |
| FCF CAGR (3Y) %i | -- | -- |
| Line item | 2025-03 | 2025-06 | 2026-03 | 2026-06 |
|---|---|---|---|---|
| ROE %i | -- | -- | -- | -31.87 |
| ROA %i | -- | -- | -38.28 | -30.49 |
| ROIC %i | -- | -- | -- | -33.00 |
| 5-year avg ROE %i | -- | -- | -- | -- |
| EBIT margin %i | -- | -- | -- | -- |
| FCF / sales %i | -- | -- | -- | -- |
| Current ratioi | -- | -- | 13.24 | 18.00 |
| Quick ratioi | -- | -- | 13.07 | 17.75 |
| Debt / assetsi | -- | -- | 2.35 | 1.14 |
| LT debt / equityi | -- | -- | -- | 0.81 |
| Interest coveragei | -- | -- | -- | -- |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- |
Quote time 2026-10-07 20:02:48 · For reference only, not investment advice and not tailored to your situation.